Literature DB >> 18249558

The endocannabinoid system in cancer-potential therapeutic target?

Jenny Flygare1, Birgitta Sander.   

Abstract

Endogenous arachidonic acid metabolites with properties similar to compounds of Cannabis sativa Linnaeus, the so-called endocannabinoids, have effects on various types of cancer. Although endocannabinoids and synthetic cannabinoids may have pro-proliferative effects, predominantly inhibitory effects on tumor growth, angiogenesis, migration and metastasis have been described. Remarkably, these effects may be selective for the cancer cells, while normal cells and tissues are spared. Such apparent tumor cell selectivity makes the endocannabinoid system an attractive potential target for cancer therapy. In this review we discuss various means by which the endocannabinoid system may be targeted in cancer and the current knowledge considering the regulation of the endocannabinoid system in malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18249558     DOI: 10.1016/j.semcancer.2007.12.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  29 in total

1.  N-acyl taurines are anti-proliferative in prostate cancer cells.

Authors:  Vicky Chatzakos; Katharina Slätis; Tatjana Djureinovic; Thomas Helleday; Mary C Hunt
Journal:  Lipids       Date:  2011-12-11       Impact factor: 1.880

2.  Cannabinoids attenuate cancer pain and proliferation in a mouse model.

Authors:  Negin Saghafi; David K Lam; Brian L Schmidt
Journal:  Neurosci Lett       Date:  2010-11-19       Impact factor: 3.046

3.  Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay.

Authors:  Hong Yin; Alan Chu; Wei Li; Bin Wang; Fabiola Shelton; Francella Otero; Deborah G Nguyen; Jeremy S Caldwell; Yu Alice Chen
Journal:  J Biol Chem       Date:  2009-03-13       Impact factor: 5.157

4.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

5.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

Review 6.  Monoacylglycerol lipase - a target for drug development?

Authors:  C J Fowler
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

7.  Revisiting CB1 receptor as drug target in human melanoma.

Authors:  István Kenessey; Balázs Bánki; Agnes Márk; Norbert Varga; József Tóvári; Andrea Ladányi; Erzsébet Rásó; József Tímár
Journal:  Pathol Oncol Res       Date:  2012-03-24       Impact factor: 3.201

Review 8.  The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

Authors:  Sean D McAllister; Liliana Soroceanu; Pierre-Yves Desprez
Journal:  J Neuroimmune Pharmacol       Date:  2015-04-28       Impact factor: 4.147

9.  GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells.

Authors:  Alexander Bondarenko; Markus Waldeck-Weiermair; Shamim Naghdi; Michael Poteser; Roland Malli; Wolfgang F Graier
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

10.  Inhibition of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide and JWH-015: involvement of CB2.

Authors:  N Olea-Herrero; D Vara; S Malagarie-Cazenave; I Díaz-Laviada
Journal:  Br J Cancer       Date:  2009-08-18       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.